Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 25, 2024

BUY
$13.42 - $23.53 $217,417 - $381,209
16,201 Added 214.72%
23,746 $506,000
Q4 2023

Feb 02, 2024

BUY
$7.58 - $14.38 $55,561 - $105,405
7,330 Added 3409.3%
7,545 $108,000
Q3 2023

Nov 01, 2023

SELL
$8.44 - $11.86 $35,684 - $50,144
-4,228 Reduced 95.16%
215 $1,000
Q2 2023

Aug 04, 2023

BUY
$9.62 - $13.99 $42,741 - $62,157
4,443 New
4,443 $47,000
Q3 2021

Oct 28, 2021

SELL
$15.42 - $21.72 $24,625 - $34,686
-1,597 Reduced 23.95%
5,070 $110,000
Q2 2021

Aug 12, 2021

BUY
$20.85 - $29.88 $82,753 - $118,593
3,969 Added 147.11%
6,667 $139,000
Q1 2021

Apr 26, 2021

SELL
$24.75 - $39.14 $372,438 - $588,978
-15,048 Reduced 84.8%
2,698 $76,000
Q4 2020

Feb 02, 2021

BUY
$29.0 - $41.62 $514,634 - $738,588
17,746 New
17,746 $579,000
Q3 2020

Oct 14, 2020

SELL
$16.3 - $30.64 $281,778 - $529,673
-17,287 Closed
0 $0
Q2 2020

Jul 13, 2020

BUY
$7.95 - $18.81 $110,854 - $262,286
13,944 Added 417.11%
17,287 $281,000
Q1 2020

Apr 29, 2020

BUY
$6.45 - $14.04 $15,583 - $33,920
2,416 Added 260.63%
3,343 $33,000
Q4 2019

Feb 05, 2020

BUY
$12.97 - $15.94 $12,023 - $14,776
927 New
927 $12,000
Q2 2019

Jul 26, 2019

SELL
$14.71 - $19.79 $3,927 - $5,283
-267 Closed
0 $0
Q1 2019

Apr 18, 2019

SELL
$13.73 - $16.87 $141,844 - $174,283
-10,331 Reduced 97.48%
267 $0
Q4 2018

Jan 16, 2019

BUY
$10.6 - $17.49 $63,684 - $105,079
6,008 Added 130.89%
10,598 $148,000
Q3 2018

Oct 23, 2018

BUY
$16.65 - $21.85 $54,278 - $71,231
3,260 Added 245.11%
4,590 $80,000
Q2 2018

Jul 30, 2018

BUY
$14.8 - $18.8 $19,684 - $25,004
1,330 New
1,330 $24,000

Others Institutions Holding KURA

About Kura Oncology, Inc.


  • Ticker KURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,893,000
  • Market Cap $598M
  • Description
  • Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...
More about KURA
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.